Company intelligence / Profile preview
Rubedo Life Sciences
Sunnyvale, California, United Statesrubedolife.com ↗
- Ownership
- Private
- Employees
- ~27
- Development stage
- Phase 1
01
Overview
Rubedo is advancing its lead candidate RLS-1496 into Phase 1 studies for chronic atopic dermatitis and chronic psoriasis. The company has developed novel senolytic compounds showing efficacy both in vitro and in vivo, with a focus on selectively targeting senescent cells while preserving healthy cells.
- Therapeutic areas
- PulmonologyMetabolic DisordersDermatologyOncologyNeurology
- Modalities
- Small moleculesprodrugs
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on Rubedo Life Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rubedo Life Sciences.